{
  "story_id": "b8efa2bb076e09d01fd0b6a85c83b5d6",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-04T19:13:05.000Z",
  "content_hash": "2ce6a27202330ce3538c6f5b18f14442be3a4ceaeafea3942634c9bcd707bce6",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Study: GLP-1 prescriptions for US children under 12 rose 300-fold since 2019",
    "dek": "Study finds GLP-1 weight-loss drug prescriptions for US children under 12 rose from 0.03% in 2019 to 9.3% by June 2026.",
    "prose": "A study published in the journal Pediatrics reported that prescriptions for GLP-1 weight-loss drugs among U.S. children under 12 rose from 0.03% in 2019 to 9.3% as of June 2026, a more than 300-fold increase. [^1]\n\nA major new study released today found that American children under 12 are now taking GLP-1 drugs to fight obesity at 300 times the rate of seven years ago. [^2]\n\nDr. Babak Orandi, lead investigator and obesity medicine specialist at NYU Langone Health, said that while absolute numbers of children under 12 receiving GLP-1 treatment are still low, GLP-1 use is accelerating rapidly and long-term safety monitoring is needed. [^3]\n\nGLP-1 weight-loss drugs are not approved for use in children under 12, but clinical guidelines allow their use for obesity in children as young as 8 in certain cases. [^4]\n\nThe study analyzed data from more than 3.5 million U.S. children aged 8 to 11 with obesity but not diabetes. [^5]\n\nGeneral medical clinical guidelines allow the use of GLP-1 drugs in children as young as 8, even though it is not illegal for doctors to prescribe them to under-12s. [^6]\n\nMore than 20,000 children aged 8 to 11 have taken GLP-1 drugs since 2019, according to an analysis of 300 million electronic medical records. [^7]\n\nThe U.S. Food and Drug Administration does not currently approve any GLP-1 drugs for children under 12 years old. [^8]",
    "cited": "[{\"statement\":\"A study published in the journal Pediatrics reported that prescriptions for GLP-1 weight-loss drugs among U.S. children under 12 rose from 0.03% in 2019 to 9.3% as of June 2026, a more than 300-fold increase.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T19:13:05.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"A major new study released today found that American children under 12 are now taking GLP-1 drugs to fight obesity at 300 times the rate of seven years ago.\",\"source\":\"The Independent\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T11:52:19.000Z\",\"publisher_count\":1,\"sources\":[\"The Independent\"]},{\"statement\":\"Dr. Babak Orandi, lead investigator and obesity medicine specialist at NYU Langone Health, said that while absolute numbers of children under 12 receiving GLP-1 treatment are still low, GLP-1 use is accelerating rapidly and long-term safety monitoring is needed.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T19:13:05.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"GLP-1 weight-loss drugs are not approved for use in children under 12, but clinical guidelines allow their use for obesity in children as young as 8 in certain cases.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T19:13:05.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"The study analyzed data from more than 3.5 million U.S. children aged 8 to 11 with obesity but not diabetes.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T19:13:05.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"General medical clinical guidelines allow the use of GLP-1 drugs in children as young as 8, even though it is not illegal for doctors to prescribe them to under-12s.\",\"source\":\"The Independent\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T11:52:19.000Z\",\"publisher_count\":1,\"sources\":[\"The Independent\"]},{\"statement\":\"More than 20,000 children aged 8 to 11 have taken GLP-1 drugs since 2019, according to an analysis of 300 million electronic medical records.\",\"source\":\"The Independent\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T11:52:19.000Z\",\"publisher_count\":1,\"sources\":[\"The Independent\"]},{\"statement\":\"The U.S. Food and Drug Administration does not currently approve any GLP-1 drugs for children under 12 years old.\",\"source\":\"The Independent\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-04T11:52:19.000Z\",\"publisher_count\":1,\"sources\":[\"The Independent\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "d1866a0ed1cc1e5f109bb3ef0ea412ae",
      "thread_id": "305026ad5b113ce63cdd4c235709dae4",
      "thread_label": "Dr. Babak Orandi",
      "novelty": "UPDATE",
      "content_hash": "e3297193108e91d14553074d61234a393fcee82ace7f7472e6314c8dd9f7698f",
      "last_published_at": "2026-09-04T19:13:05.000Z",
      "read_receipt": {
        "slice_hash": "9c69d9730b8bd17104085e79f74e1a4efef5a04f5f6abba71ea09b0703f9c6bc",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDRUMTg6MDE6MDAuMDAwMDAwWiIsImlkIjoiNDM2Y2FhODVhZGY5YzZmODIwOGIxNDJiYzM5ZWRjYWMiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDRUMjE6MzA6MDkuMDAwMDAwWiIsImlkIjoiYmVhZjQxZWQ0ODJiNmEwYThmZWFhZDJmNmMyYTdjZmEiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 8103881,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "QGKP8ErwhgOPvWKjMKa-3fV0B2sfg38R9xvdMRLgkKbByUGkFwlFOLugrl03UCd9BIMbjf9bTt-Cy7yZGdFaBg",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-05T00:35:27.567Z"
  },
  "cited_facts": [
    {
      "statement": "A study published in the journal Pediatrics reported that prescriptions for GLP-1 weight-loss drugs among U.S. children under 12 rose from 0.03% in 2019 to 9.3% as of June 2026, a more than 300-fold increase.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T19:13:05.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "A major new study released today found that American children under 12 are now taking GLP-1 drugs to fight obesity at 300 times the rate of seven years ago.",
      "source": "The Independent",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T11:52:19.000Z",
      "publisher_count": 1,
      "sources": [
        "The Independent"
      ]
    },
    {
      "statement": "Dr. Babak Orandi, lead investigator and obesity medicine specialist at NYU Langone Health, said that while absolute numbers of children under 12 receiving GLP-1 treatment are still low, GLP-1 use is accelerating rapidly and long-term safety monitoring is needed.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T19:13:05.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "GLP-1 weight-loss drugs are not approved for use in children under 12, but clinical guidelines allow their use for obesity in children as young as 8 in certain cases.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T19:13:05.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "The study analyzed data from more than 3.5 million U.S. children aged 8 to 11 with obesity but not diabetes.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T19:13:05.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "General medical clinical guidelines allow the use of GLP-1 drugs in children as young as 8, even though it is not illegal for doctors to prescribe them to under-12s.",
      "source": "The Independent",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T11:52:19.000Z",
      "publisher_count": 1,
      "sources": [
        "The Independent"
      ]
    },
    {
      "statement": "More than 20,000 children aged 8 to 11 have taken GLP-1 drugs since 2019, according to an analysis of 300 million electronic medical records.",
      "source": "The Independent",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T11:52:19.000Z",
      "publisher_count": 1,
      "sources": [
        "The Independent"
      ]
    },
    {
      "statement": "The U.S. Food and Drug Administration does not currently approve any GLP-1 drugs for children under 12 years old.",
      "source": "The Independent",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-04T11:52:19.000Z",
      "publisher_count": 1,
      "sources": [
        "The Independent"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}